Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone.

@article{Xiao2015PhysiologicallyBP,
  title={Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone.},
  author={Qingqing Xiao and Liling Tang and Ruijuan Xu and Wei Qian and Jin Yang},
  journal={Biopharmaceutics & drug disposition},
  year={2015},
  volume={36 9},
  pages={603-12}
}
PURPOSE Repaglinide and pioglitazone are both CYP2C8 and CYP3A4 substrates. This study was to determine whether repaglinide has an inhibitory effect on the metabolism of pioglitazone in vitro, in silico and in vivo. METHOD In vitro, the effect of repaglinide on the metabolism of pioglitazone was assessed in pooled human liver microsomes. In silico, an IVIVE-PBPK linked model was built with Simcyp®. Then, a randomized, 2-phase cross-over clinical study was conducted in 12 healthy volunteers… CONTINUE READING